Page last updated: 2024-12-08

gadofosveset trisodium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

gadofosveset trisodium: a low molecular weight molecule chelated to Gadolinium, that strongly binds to plasma proteins; Vasovist is an injectable for imaging the vascular system by magnetic resonance angiography [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23724913
MeSH IDM0458591

Synonyms (8)

Synonym
ablavar (tn)
D04286
gadofosveset trisodium
193901-90-5
Q5516411
trisodium;2-[[2-[bis(carboxylatomethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydrate
gadolinium sodium 4-(bis(carboxylatomethyl)amino)-6,9-bis(carboxylatomethyl)-1-((4,4-diphenylcyclohexyl)oxy)-1-oxido-2-oxa-6,9-diaza-1-phosphaundecan-11-oate 1-oxide hydrate (1:3:1:1)
DTXSID501027793

Research Excerpts

Toxicity

Most reactions after gadofosveset trisodium administration in children and young adults are mild. Severe allergiclike reactions occur, so policies must be in place to treat patients with adverse reactions when using this contrast agent.

ExcerptReferenceRelevance
"There were no severe or serious adverse events."( Carotid MR angiography: phase II study of safety and efficacy for MS-325.
Baum, RA; Bis, KG; Bluemke, DA; D'Agostino, R; Grist, TM; Malden, ES; Pierro, JA; Stillman, AE; Yucel, EK, 2001
)
0.31
" All patients were monitored for adverse events with hematologic analysis, analysis of blood chemistry, urinalysis, and electrocardiographic parameters; these methods were analyzed to determine safety."( Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study.
Blebea, J; Duerinckx, A; Foster, GS; Johnson, SP; Kent, KC; Meranze, SG; Middlebrook, MR; Moneta, G; Muluk, S; Narra, VR; Pollak, J; Quinn, SF; Rapp, JH; Rofsky, NM; Shamsi, K; Soto, JA; Toombs, BD; Weisskoff, RM; Wolff, SD; Yucel, EK, 2005
)
0.33
" The most common adverse events were as follows: feeling hot, 12 (4."( Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study.
Blebea, J; Duerinckx, A; Foster, GS; Johnson, SP; Kent, KC; Meranze, SG; Middlebrook, MR; Moneta, G; Muluk, S; Narra, VR; Pollak, J; Quinn, SF; Rapp, JH; Rofsky, NM; Shamsi, K; Soto, JA; Toombs, BD; Weisskoff, RM; Wolff, SD; Yucel, EK, 2005
)
0.33
"On the basis of substantial improvements over non-contrast MR angiography in efficacy and a minimal and transient side-effect profile, gadofosveset was found to be safe and effective for MR angiography in patients known or suspected to have peripheral vascular disease."( Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study.
Blebea, J; Duerinckx, A; Foster, GS; Johnson, SP; Kent, KC; Meranze, SG; Middlebrook, MR; Moneta, G; Muluk, S; Narra, VR; Pollak, J; Quinn, SF; Rapp, JH; Rofsky, NM; Shamsi, K; Soto, JA; Toombs, BD; Weisskoff, RM; Wolff, SD; Yucel, EK, 2005
)
0.33
" Incidence of severe and serious adverse events with MS-325 was low."( MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.
Bertoni, H; Breger, R; Edelman, M; Goyen, M; Mohler, ER; O'Riordan, E; Perreault, P; Shamsi, K; Sharafuddin, M; Siragusa, D; Taylor, J; Weisskoff, RM; Yucel, EK, 2005
)
0.33
"03 mmol/kg and was safe and effective for MR evaluation of patients with aortoiliac occlusive disease."( MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.
Bertoni, H; Breger, R; Edelman, M; Goyen, M; Mohler, ER; O'Riordan, E; Perreault, P; Shamsi, K; Sharafuddin, M; Siragusa, D; Taylor, J; Weisskoff, RM; Yucel, EK, 2005
)
0.33
"03 mmol/kg in humans and the doses resulting in adverse effects in animal studies."( Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography.
Graham, PB; Müller, S; Schweinfurth, H; Steger-Hartmann, T, 2006
)
0.33
" Overall safety data were pooled from 8 studies and included adverse event monitoring, clinical laboratory assays, vital signs, oxygen saturation, physical examination, and electrocardiography."( A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.
Chamberlin, P; Shamsi, K; Yucel, EK, 2006
)
0.33
"In pooled data, treatment related adverse events were reported by 176 (22."( A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.
Chamberlin, P; Shamsi, K; Yucel, EK, 2006
)
0.33
" The overall rate and experience of adverse events was similar to that of placebo."( A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.
Chamberlin, P; Shamsi, K; Yucel, EK, 2006
)
0.33
"03-mmol/kg group, 28% of patients reported a total of 50 adverse events, 96% of which were reported as mild or moderate."( Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study.
Bosch, E; Kreitner, KF; Parsons, EC; Peirano, MF; Shamsi, K; Thurner, S; Thurnher, S, 2008
)
0.35
" A prudent approach would be to (1) identify patients at high risk to develop contrast-related complications, (2) use noncontrast-based imaging techniques in these patients, as long as they are suitably diagnostic and safe and (3) if the risk:benefit ratio of the imaging information favors a contrast-based study, then appropriate prophylactic steps and use of contrast agents with the lowest risk of complication should be used after obtaining informed consent."( Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella, MA; Reilly, RF, 2011
)
0.37
"The purpose of this retrospective study was to systematically search for acute adverse reactions and long-term complications in all patients that had been administered gadofosveset at our hospital."( Safety aspects of gadofosveset in clinical practice--analysis of acute and long-term complications.
Akeson, P; Akesson, M; Alhadad, A; Leander, P; Lehti, L; Sterner, G; Wassélius, J, 2014
)
0.4
" Radiological information system (RIS) and clinical patient records were analyzed for suspected acute adverse reactions and long-term complications including nephrogenic systemic fibrosis (NSF)."( Safety aspects of gadofosveset in clinical practice--analysis of acute and long-term complications.
Akeson, P; Akesson, M; Alhadad, A; Leander, P; Lehti, L; Sterner, G; Wassélius, J, 2014
)
0.4
"No acute adverse events or technical failures related to the contrast medium were recorded in the RIS."( Safety aspects of gadofosveset in clinical practice--analysis of acute and long-term complications.
Akeson, P; Akesson, M; Alhadad, A; Leander, P; Lehti, L; Sterner, G; Wassélius, J, 2014
)
0.4
"Based on our clinical material we conclude that gadofosveset is safe for a mixed patient population with no acute adverse events or any indications of long-term complications during the follow-up time up to four years."( Safety aspects of gadofosveset in clinical practice--analysis of acute and long-term complications.
Akeson, P; Akesson, M; Alhadad, A; Leander, P; Lehti, L; Sterner, G; Wassélius, J, 2014
)
0.4
"The objective of our study was to determine the adverse reaction rate associated with the administration of blood pool contrast material in children and young adults."( Safety of Blood Pool Contrast Agent Administration in Children and Young Adults.
Boylan, EE; deFreitas, RA; Nelson, P; Orr, RJ; Popescu, AR; Rigsby, CK; Schoeneman, S, 2015
)
0.42
" A review of the electronic medical records identified adverse reactions recorded within 24 hours of contrast administration."( Safety of Blood Pool Contrast Agent Administration in Children and Young Adults.
Boylan, EE; deFreitas, RA; Nelson, P; Orr, RJ; Popescu, AR; Rigsby, CK; Schoeneman, S, 2015
)
0.42
"7 years) received 711 doses of gadofosveset trisodium; 137 adverse reactions were recorded, which yields a 19."( Safety of Blood Pool Contrast Agent Administration in Children and Young Adults.
Boylan, EE; deFreitas, RA; Nelson, P; Orr, RJ; Popescu, AR; Rigsby, CK; Schoeneman, S, 2015
)
0.42
"Most reactions after gadofosveset trisodium administration in children and young adults are mild; however, severe allergiclike reactions occur, so policies must be in place to treat patients with adverse reactions when using this contrast agent."( Safety of Blood Pool Contrast Agent Administration in Children and Young Adults.
Boylan, EE; deFreitas, RA; Nelson, P; Orr, RJ; Popescu, AR; Rigsby, CK; Schoeneman, S, 2015
)
0.42
"Based on the results of this retrospective safety analysis of up to 14 years following 1-2 exposures, we conclude that Gadofosveset in clinical practice is safe in the long-term."( Long-term safety of Gadofosveset in clinical practice.
Åkesson, M; Leander, P; Lehti, L; Sterner, G; Wassélius, J, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"14 L/kg, and a long elimination half-life (Te1/2), 2 to 3 hours."( Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging.
Lauffer, RB; Ouellet, HS; Parmelee, DJ; Walovitch, RC, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" The main effect of repeated dosing in both rats and monkeys was vacuolation in kidney proximal tubules without concomitant effect on kidney function."( Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography.
Graham, PB; Müller, S; Schweinfurth, H; Steger-Hartmann, T, 2006
)
0.33
" The greater relaxation enhancement and more favorable dosing profile make blood-pool agents superior to standard agents for use in cerebral time-resolved MRA."( Improved quality and diagnostic confidence achieved by use of dose-reduced gadolinium blood-pool agents for time-resolved intracranial MR angiography.
Dehkharghani, S; Kang, J; Saindane, AM, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (257)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (3.11)18.2507
2000's85 (33.07)29.6817
2010's161 (62.65)24.3611
2020's3 (1.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials32 (12.08%)5.53%
Reviews21 (7.92%)6.00%
Case Studies9 (3.40%)4.05%
Observational0 (0.00%)0.25%
Other203 (76.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]